SOX2 and cancer: Patients with SOX2-positive tumors exhibited significantly worse overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS; P=0.004, P=0.005 and P=0.011, respectively) during a median follow-up period of 39.3 months.